OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Raez on the KEYNOTE-407 Trial in Squamous NSCLC

October 8th 2019

Luis E. Raez, MD, discusses the impact of the KEYNOTE-407 trial in squamous non–small cell lung cancer.

Dr. Hoimes on EV-103 Results in Urothelial Cancer

October 8th 2019

Christopher J. Hoimes, DO, discusses the results of the EV-103 trial in patients with locally advanced or metastatic urothelial cancer.

Dr. Gerson on the Watch-and-Wait Approach in MCL

October 7th 2019

James N. Gerson, MD, discusses the watch-and-wait approach for patients with mantle cell lymphoma.

Dr. Bates on Stimulating the Immune System With Nanoparticles in RCC

October 7th 2019

Paula J. Bates, PhD, discusses the use of nanoparticles to stimulate the immune system in renal cell carcinoma.

Dr. Agarwal on the Safety Profile of Enzalutamide/Talazoparib in mCRPC

October 7th 2019

Neeraj Agarwal, MD, discusses the safety profile of the combination of enzalutamide and talazoparib in patients with metastatic castration-resistant prostate cancer.

Dr. Bekaii-Saab on the Rationale to Evaluate Atezolizumab/Bevacizumab in MSS mCRC

October 5th 2019

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the rationale to evaluate atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Dr. Eradat Discusses Data With Acalabrutinib in CLL

October 5th 2019

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses data with acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Dr. Borghaei on Anticipated Trials Evaluating Immunotherapy in NSCLC

October 5th 2019

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses necessary research and anticipated trials evaluating immunotherapy in advanced non–small cell lung cancer (NSCLC).

Dr. Hsieh on Unmet Needs of Rare Kidney Cancer Variants

October 4th 2019

James J. Hsieh, MD, PhD, discusses unmet needs in non-clear cell renal cell carcinoma.

Dr. Smith on Utilizing Lenalidomide in CLL

October 4th 2019

Mitchell R. Smith, MD, PhD, discusses the potential advantage of lenalidomide in chronic lymphocytic leukemia.

Dr. Rule on the Future Therapeutic Landscape of MCL

October 4th 2019

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the future therapeutic landscape of mantle cell lymphoma.

Dr. Cristofanilli on Lasofoxifene in ESR1-Mutant Breast Cancer

October 4th 2019

Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the use of lasofoxifene in ESR1-mutant breast cancer.

Dr. Pal on CRISPR-Based Technology in RCC

October 4th 2019

Sumanta Kumar Pal, MD, discusses potential developments with vaccines and CRISPR/Cas9 technology coming down the pipeline in renal cell carcinoma.

Dr. Sotomayor on the Durability of CAR T Cells in Hematologic Malignancies

October 4th 2019

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses the durability of CAR T cells, as well as ways to combat immune escape mechanisms in hematologic malignancies.

Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLL

October 4th 2019

James N. Gerson, MD, discusses the phase III CLL14 trial evaluating the combination of venetoclax and obinutuzumab versus chlorambucil and obinutuzumab as frontline therapy in chronic lymphocytic leukemia.

Dr. Mudad on RELAY Trial for EGFR-Mutant NSCLC

October 3rd 2019

Raja Mudad, MD, FACP, discusses the RELAY trial and using doublet therapy to treat EGFR-mutant non–small cell lung cancer.

Dr. Atkins on CA209-004 Trial Results in Advanced Melanoma

October 3rd 2019

Michael B. Atkins, MD, discusses results from the CA209-004 trial, which was a phase I study analyzing patients with advanced, unresectable melanoma treated with nivolumab plus ipilimumab.

Dr. Manji on Lack of Actionable Targets in Patients with Colorectal Cancer

October 2nd 2019

Gulam A. Manji, MD, PhD, discusses the importance of discovering other actionable targets for patients with colorectal cancer.

Dr. Bhatt on Identification of Immune Checkpoint Pathway in RCC

October 2nd 2019

Rupal S. Bhatt, MD, PhD, discusses the discovery of HHLA2/KIR3DL3, a novel therapeutic immune checkpoint pathway in renal cell carcinoma.

Dr. Hochster on Take-Home Message of the POLO Trial in Pancreatic Cancer

October 2nd 2019

Howard S. Hochster, MD, FACP, discusses important takeaways from the randomized, double-blind, phase III POLO trial in pancreatic cancer.